Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Sentinel: Sentinel System 3.0 IDIQ

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Food and Drug Administration is launching the Sentinel 3.0 System in fiscal year 2026, an initiative developed from the experience of the Sentinel 2.0 System, the BEST Initiative, and Medical Device Active Surveillance. This new system integrates foundational work involving EHR and administrative claims data, guidance from CDER, CBER, and CDRH leadership, and extensive feedback from public workshops and Requests for Information. The operational structure consists of the Sentinel Coordinating Center, managed by a core team across various FDA offices, and a Program Management Organization that provides business informatics and project management via a FedRAMP cloud-based environment. Additionally, the system incorporates a Data Hub consisting of Data Partners and a Data Platform, supported by Scientific Support Services. This effort is organized as an IDIQ forecast under NAICS code 541714.

General Info

FDA is launching Sentinel 3.0 in 2026 via an IDIQ for system integration.

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

USA

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyFood and Drug Administration → Food And Drug Administration
Contacts2 people available
OfficeN/A
Office AddressN/A
Contacts
Cder Acquisition Liaison
To Be Determined To Be DeterminedContracting Officer

Full Description

Show more
FDA is launching the new Sentinel 3.0 System in fiscal year 2026 based on 1) FDA's experience using the Sentinel 2.0 System, BEST Initiative, and Medical Device Active Surveillance, 2) the foundational work conducted by both the Sentinel 2.0 Innovation Center and BEST programmatic work using EHR data linked to administrative claims data during the 2019 to 2025 contract cycle, 3) the guidance provided by CDER, CBER, and CDRH Senior Leadership, 4) input received through responses to four Requests for Information (RFI) related to the Sentinel 3.0 System recompete,10 and 5) input received from the public through questions and comments received by FDA after the 2024 16th Annual Sentinel 3.0 Initiative Public Workshop.(1) FDA Sentinel Coordinating Center (SCC): The SCC will be managed by the Sentinel 3.0 Core Team (SCT) in CDER's OSE, in the OBPV's Surveillance Program Staff (CSPS), in CDRH's Office of Clinical Evidence and Analysis (OCEA), and Office of the Commissioner (OC).(2) Sentinel Program Management Organization (PMO): The PMO, via a contract awarded in September 202412, provides program/project management and business informatics support services (e.g., Collaboration Platform that operates outside of FDA in a Federal Risk and Authorization Management Program (FedRAMP) cloud-based environment).(3) Data Hub and Scientific Support Services: The Data Hub, comprising Data Partners and the Data Platform, along with Scientific Support Services

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Grant
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Solicitation # RFA-NS-28-012
The National Institutes of Health, under the Department of Health and Human Services, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). This includes Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program funds the entire translational pipeline, from therapeutic lead optimization and drug product development to IND-enabling studies and early first-in-human clinical evaluations. Key activities include optimizing editing constructs and delivery systems, demonstrating in vivo efficacy, conducting safety pharmacology and toxicology studies, and developing scalable manufacturing processes that align with regulatory expectations. The agency intends to commit 6 million dollars in both fiscal years 2028 and 2029, with an expected three awards and a maximum project period of five years. Individual annual budget caps are set at 1.3 million dollars in direct costs, increasing to 2.5 million dollars for projects involving clinical trials. Awards are governed by the Public Health Service Act and federal regulations 42 CFR Part 52 and 2 CFR Part 200. Evaluation is based on an Overall Impact Score considering significance, innovation, approach, investigator expertise, and environment, with a specific focus on the Target Product Profile and the use of quantitative Go/No-Go milestones. Eligible applicants include small businesses and other for-profit organizations. Requirements for submission include active registration in the System for Award Management, a Unique Entity Identifier, and eRA Commons accounts. Awardees must adhere to strict cybersecurity incident reporting protocols, notifying the agency within 48 hours of discovery, and must register applicable clinical trials with ClinicalTrials.gov. The solicitation features multiple application cycles with deadlines extending through October 10, 2028, and earliest start dates ranging from December 2027 to July 2029.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in almost 2 years
View Details
NAICS: 541714
New
Grant
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Solicitation # PAR-28-042
Solicitation PAR-28-042, issued by the National Institutes of Health under the Department of Health and Human Services, is a funding opportunity designed to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer. The program focuses on tools for cancer detection, diagnosis, prognosis, monitoring, and the prediction of treatment response or toxicity. Funding is available through either a phased UH2/UH3 mechanism or a standalone UH3 mechanism to facilitate laboratory optimization and clinical validation using human samples. Key deliverables include the demonstration of assay results associated with clinical endpoints, the establishment of statistical cut-off values, and the definition of sensitivity and specificity. All clinical laboratories must adhere to CLIA, GLP, or ISO 17025 standards. Awards are determined via a peer review system based on an overall impact score, evaluating the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Specific evaluation criteria include the clarity of milestones for transitioning from UH2 to UH3 phases and the adequacy of commercialization plans. Eligible applicants include small businesses, for-profit organizations, higher education institutions, and 501(c)(3) nonprofits. Applicants must maintain active registrations in SAM.gov, eRA Commons, and Grants.gov. Additionally, recipients must comply with strict cybersecurity incident reporting requirements, notifying the agency within 48 hours of discovery, and ensure all human subject protocols are reviewed by an Institutional Review Board or Independent Ethics Committee.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in about 3 years
View Details
NAICS: 541714
New
Federal
DNA Sequencing Service
Solicitation # PCA-NIEHS-00080
The National Institutes of Health, through the National Institute of Environmental Health Sciences, is issuing a Small Business Sources Sought notice for solicitation PCA-NIEHS-00080 to identify capable providers for an indefinite-delivery indefinite-quantity contract. The requirement is for DNA sequencing services and associated bioinformatics support, primarily utilizing Sanger sequencing with a smaller volume of high-throughput whole-plasmid sequencing. The estimated workload is between 2,000 and 3,000 samples per month, including yeast colonies, plasmid DNA, and PCR-generated samples from human and rodent species. The intended period of performance is five years from the date of award, with a potential six-month extension per FAR 52.217-8. The selected contractor must provide a web-based ordering and tracking system, all necessary sample collection and shipping materials, and a reliable transportation method for samples from the NIEHS campus in Research Triangle Park, North Carolina. Key technical requirements include maintaining a Phred-equivalent quality score greater than 20 for sequencing and ensuring successful PCR amplification produces a single DNA band of the expected size. The contractor is responsible for preserving remaining DNA for at least 180 days and returning unused primers to the government. Administrative requirements include submitting invoices within ten business days of the billing cycle and maintaining strict confidentiality of all sequencing data. This notice is specifically targeting small business concerns, including 8(a), SDB, WOSB, HUBZone, VOSB, and SDVOSB designations. Interested parties must submit a capability statement of no more than seven pages, including their UEI, TIN, and business size certification, to Luz Casey by November 12, 2026.
National Institutes Of Health Olao

POSTED

2 days ago

DEADLINE

in 8 days
View Details
NAICS: 541714
New
Federal
FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Solicitation # FDABAA-27-00123
The FY27 FDA Broad Agency Announcement (BAA), solicitation number FDABAA-27-00123, seeks basic and applied research and development proposals to advance regulatory science and innovation. Managed by the FDA Office of Acquisitions and Grant Services, this initiative aims to utilize capabilities from industry and academia to improve technologies, materials, processes, and methods that support the FDA's mission to protect and promote national health. The BAA is open to all responsible sources, with strong encouragement for small business participation. Proposals are evaluated based on overall best value, focusing on scientific and technical merit, the degree of innovation, the feasibility of proposed plans, and the potential to overcome critical barriers in the field. Submissions must be delivered as searchable PDFs via email by January 22, 2027, at 5:00 PM EST. The application process requires a concept paper limited to three pages and a full proposal divided into a technical volume (50-page limit) and a cost volume. Key requirements include valid SAM.gov registration, adherence to strict page limits, and the provision of detailed key personnel qualifications. Awardees must comply with specific regulatory standards, including Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP) where applicable. Additionally, contractors must maintain strict organizational conflict of interest disclosures and provide monthly technical progress reports. Non-small business concerns submitting proposals exceeding 900,000 dollars are required to provide a Small Business Subcontracting Plan.
FDA Office Of Acq Grant Svcs

POSTED

5 days ago

DEADLINE

in 3 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS